BeiGene Ltd (NAS:BGNE)

$ 205.75 -9.25 (-4.3%) Market Cap: 23.54 Bil Enterprise Value: 22.24 Bil PE Ratio: 0 PB Ratio: 6.36 GF Score: 81/100

Beigene Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Beigene Ltd Investors and Analysts Panel Event Presentation Transcript
Dec 11, 2023
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Beigene Ltd Investor Research and Development Day Transcript
Jul 18, 2023
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2023
Beigene Ltd at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Beigene Ltd to Discuss Final Results of the ALPINE Trial Late-Breaker Presentation Transcript
Dec 13, 2022
Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call Transcript
Dec 12, 2022
Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Beigene Ltd at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022
Beigene Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Beigene Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Beigene Ltd R&D Day Transcript
Aug 25, 2021
Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call Transcript
Jun 11, 2021
Beigene Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call Transcript
Dec 29, 2020
Beigene Ltd at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Beigene Ltd to Discuss the Company's Early Development Pipeline and Research Call Transcript
Jul 09, 2020
Beigene Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Beigene Ltd at American Society of Clinical Oncology (ASCO) Virtual Scientific Program Call Transcript
May 30, 2020
Beigene Ltd at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Beigene Ltd Update Call: ASPEN Trial Readout Transcript
Dec 16, 2019
Beigene Ltd Corporate Update: Global Strategic Oncology Collaboration with Amgen Transcript
Nov 01, 2019
Beigene Ltd at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Beigene Ltd Update Call Transcript
Sep 08, 2019
Beigene Ltd Conference Call to Discuss Clinical Data on Zanubrutinib at 15th International Conference on Malignant Lymphoma (ICML) Transcript
Jun 20, 2019
Beigene Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019
Beigene Ltd at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Q4 2018 Beigene Ltd Earnings Call Transcript
Feb 27, 2019

$139.97 (-0.04%)

Earnings

Beigene Ltd to Discuss Interim Analysis of the ALPINE Trial and Data Presented at EHA2021 Call Transcript

Jun 11, 2021 / 04:00PM GMT

Release Date Price: $346.91 (-1.72%)

Transcript

Heng Liang

BeiGene, Ltd. - CFO & Chief Strategy Officer

Good afternoon and good evening. This is Howard Liang. I'm the CFO and Chief Strategy Officer of BeiGene. Welcome to our ALPINE Results and the EHA 2021 Update Zoom Webinar.

I'd like to first thank everyone for taking time out of your busy schedule to join us, especially those joining us from Asia in the late night. We're very excited to provide you with the latest results of the ALPINE study, which, as many of you know, is our head-to-head Phase III study comparing BRUKINSA to ibrutinib in relapsed refractory CLL patients.

The data were just presented by Professor Hillmen at the -- principal investigator of the study, at the Presidential Symposium of EHA about 45 minutes ago.

Next slide. During this call, Professor Hillmen will recap the ALPINE presentation at EHA. After that, Professor Jennifer Brown from Dana-Farber and Harvard Medical School will provide perspectives of the results. This will be followed by an overview of the BRUKINSA development program by Dr. Jane Huang, the CMO of Hematology at Beijing; and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.